PSORS3
MCID: PSR024
MIFTS: 28

Psoriasis 3 (PSORS3)

Categories: Genetic diseases, Immune diseases, Rare diseases, Skin diseases

Aliases & Classifications for Psoriasis 3

MalaCards integrated aliases for Psoriasis 3:

Name: Psoriasis 3 56 12 15
Psoriasis Susceptibility 3 56 13
Psors3 56 12
Psoriasis 3, Susceptibility to 56

Classifications:



External Ids:

Disease Ontology 12 DOID:0111283
OMIM 56 601454
OMIM Phenotypic Series 56 PS177900

Summaries for Psoriasis 3

Disease Ontology : 12 A psoriasis that has material basis in variation in a region on chromosome 4q.

MalaCards based summary : Psoriasis 3, also known as psoriasis susceptibility 3, is related to psoriasis and skin disease. An important gene associated with Psoriasis 3 is PSORS3 (Psoriasis Susceptibility 3). The drugs Clobetasol and Certolizumab pegol have been mentioned in the context of this disorder. Affiliated tissues include skin, lung and testes.

More information from OMIM: 601454 PS177900

Related Diseases for Psoriasis 3

Graphical network of the top 20 diseases related to Psoriasis 3:



Diseases related to Psoriasis 3

Symptoms & Phenotypes for Psoriasis 3

Clinical features from OMIM:

601454

Drugs & Therapeutics for Psoriasis 3

Drugs for Psoriasis 3 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 13)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Clobetasol Approved, Experimental, Investigational Phase 3 25122-41-2, 25122-46-7 32798 5311051
2
Certolizumab pegol Approved 428863-50-7
3
Adalimumab Approved 331731-18-1 16219006
4
Etanercept Approved, Investigational 185243-69-0
5 Analgesics, Non-Narcotic
6 Immunologic Factors
7 Immunosuppressive Agents
8 Analgesics
9 Anti-Inflammatory Agents
10 Gastrointestinal Agents
11 Antirheumatic Agents
12 Anti-Inflammatory Agents, Non-Steroidal
13
dipyrone 522325

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Subject Preference Comparison Between Clobetasol Propionate Shampoo, 0.05% and Three Other Topical Corticosteroids in the Treatment of Moderate to Severe Scalp Psoriasis Completed NCT00438399 Phase 3 C. propionate - Corticosteroid 1;C. propionate- Corticosteroid 2;C. propionate -Corticosteroid 3;Corticosteroid 1- C. propionate;Corticosteroid 2 - C. propionate;Corticosteroid 3 - C. propionate
2 A Phase 2, Randomized, Double-Blind, Multicenter, Parallel-Group, Placebo-Controlled Study to Assess the Efficacy and Safety of Three Dose Levels of XP23829 in Subjects With Moderate-to-Severe Chronic Plaque-Type Psoriasis Completed NCT02173301 Phase 2 XP23829 400 mg QD;XP 23829 800 mg QD;XP23829 400 mg BID;Placebo
3 An Observational Study Evaluating the Utility of Ultrasound Confirmed Enthesitis as a Prognostic Marker for Response to Biologic Therapy in Psoriatic Arthritis Recruiting NCT03955861
4 Serum Level of Bioactive Mediators and Urinary Biopyrins in Psoriasis Not yet recruiting NCT03889938

Search NIH Clinical Center for Psoriasis 3

Genetic Tests for Psoriasis 3

Anatomical Context for Psoriasis 3

MalaCards organs/tissues related to Psoriasis 3:

40
Skin, Lung, Testes, Tonsil

Publications for Psoriasis 3

Articles related to Psoriasis 3:

(show all 49)
# Title Authors PMID Year
1
Involvement of interleukin-21 in the epidermal hyperplasia of psoriasis. 56
19684581 2009
2
A genome-wide association study of psoriasis and psoriatic arthritis identifies new disease loci. 56
18369459 2008
3
Analysis of three suggested psoriasis susceptibility loci in a large Swedish set of families: confirmation of linkage to chromosome 6p (HLA region), and to 17q, but not to 4q. 56
9858851 1999
4
Evidence for two psoriasis susceptibility loci (HLA and 17q) and two novel candidate regions (16q and 20p) by genome-wide scan. 56
9259283 1997
5
Evidence that a locus for familial psoriasis maps to chromosome 4q. 56
8841203 1996
6
Norwegian Coronavirus Disease 2019 (NO COVID-19) Pragmatic Open label Study to assess early use of hydroxychloroquine sulphate in moderately severe hospitalised patients with coronavirus disease 2019: A structured summary of a study protocol for a randomised controlled trial. 61
32503662 2020
7
A Belgian consensus on the definition of a treat-to-target outcome set in psoriasis management. 61
31749264 2020
8
Therapeutic management of adults with atopic dermatitis: comparison with psoriasis and chronic urticaria. 61
32119144 2020
9
Prevalence of skin disorders and associated socio-economic factors among primary school children in the Eastern region of Saudi Arabia. 61
31431774 2019
10
Circumscribed Juvenile Pityriasis Rubra Pilaris (Type 4) Koebnerising after a Hot Water Burn: Mild Disease with Maximum Koebner Response. 61
31032794 2019
11
Long-term efficacy and safety of secukinumab in Japanese patients with moderate to severe plaque psoriasis: 3-year results of a double-blind extension study. 61
30672623 2019
12
The multifaceted presentation of chronic recurrent multifocal osteomyelitis: a series of 486 cases from the Eurofever international registry. 61
29596638 2018
13
Association of Psoriasis With Comorbidity Development in Children With Psoriasis. 61
29322175 2018
14
Psychosocial Distress of Patients with Psoriasis: Protocol for an Assessment of Care Needs and the Development of a Supportive Intervention. 61
29415875 2018
15
A Case of Ceftriaxone-Induced Acute Generalized Exanthematous Pustulosis/Generalized Pustular Psoriasis Overlap. 61
29681811 2018
16
Comparative Effectiveness of Adalimumab versus Secukinumab for the Treatment of Psoriatic Arthritis: A Matching-Adjusted Indirect Comparison. 61
28762213 2017
17
Biosimilars: An Update on Clinical Trials (Review of Published and Ongoing Studies). 61
28511752 2017
18
[Evidence-based Indications for Tonsillectomy]. 61
27128404 2016
19
Indications for tonsillectomy stratified by the level of evidence. 61
28025609 2016
20
Association of Extrahepatic Manifestations with Autoimmune Hepatitis. 61
26641498 2015
21
Development and testing of new candidate psoriatic arthritis screening questionnaires combining optimal questions from existing tools. 61
24470406 2014
22
Respiratory failure due to infliximab induced interstitial lung disease. 61
23969008 2013
23
Balance of Treg vs. T-helper cells in the transition from symptomless to lesional psoriatic skin. 61
23330679 2013
24
[Guidelines for high-quality use of biologic therapies in adults with plaque psoriasis]. 61
22985925 2012
25
Prevalence of metabolic syndrome in patients with psoriasis: a population-based study in the United Kingdom. 61
22113483 2012
26
New-onset psoriasis associated with adalimumab: a report of two cases. 61
21971280 2011
27
Assessor-blinded study of the metabolic syndrome and surrogate markers of increased cardiovascular risk in children with moderate-to-severe psoriasis compared with age-matched population of children with warts. 61
21818512 2011
28
A case series of kaposi's varicelliform eruption in dermatology in-patients in a tertiary care centre. 61
21572809 2011
29
Histopathologic spectrum of psoriasiform skin reactions associated with tumor necrosis factor-α inhibitor therapy. A study of 16 biopsies. 61
20520526 2010
30
Efficacy and tolerability of a cosmetically acceptable coal tar solution in the treatment of moderate plaque psoriasis: a controlled comparison with calcipotriene (calcipotriol) cream. 61
20513160 2010
31
[Efficacy of TNF-alpha antagonists for plaque-type psoriasis: a systematic review and graphical presentation]. 61
19361697 2009
32
A randomized comparison of acitretin-narrow-band TL-01 phototherapy and acitretin-psoralen plus ultraviolet A for psoriasis. 61
19002344 2008
33
Are patients with psoriasis undertreated? Results of National Psoriasis Foundation survey. 61
17706322 2007
34
Psoriasis of the face and flexures. 61
17907013 2007
35
European patient perspectives on the impact of psoriasis: the EUROPSO patient membership survey. 61
16965422 2006
36
Does inflammatory linear verrucous epidermal nevus represent a segmental type 1/type 2 mosaic of psoriasis? 61
16484814 2006
37
Evaluation of the IRF-2 gene as a candidate for PSORS3. 61
14962090 2004
38
Psoriatic nails: a prospective clinical study. 61
12879333 2003
39
Evidence for a major psoriasis susceptibility locus at 6p21(PSORS1) and a novel candidate region at 4q31 by genome-wide scan in Chinese hans. 61
12485440 2002
40
[Efficacy of tonsillectomy on psoriasis and tonsil histology]. 61
11766391 2001
41
Fine mapping of the PSORS4 psoriasis susceptibility region on chromosome 1q21. 61
11348461 2001
42
Levels of proelafin peptides in the sera of the patients with generalized pustular psoriasis and pustulosis palmoplantaris. 61
10877128 2000
43
Duration of remission during maintenance cyclosporine therapy for psoriasis. Relationship to maintenance dose and degree of improvement during initial therapy. 61
7611794 1995
44
[Interferon and diseases]. 61
7523746 1994
45
Methimazole (2-mercapto 1-methyl imidazole) in psoriasis--results of an open trial. 61
8324273 1993
46
[The initial clinical experience of using Ovosorb antiprotease hemosorbent in the combined treatment of dermatoses]. 61
1805413 1991
47
Hidden psoriatic arthritis in seronegative oligoarthritis: a 14-year follow-up study. 61
2612119 1989
48
Cascade filtration: clinical application in 26 patients with immune complex and IgM mediated diseases. 61
6230324 1983
49
Psoriasis: odd varieties in the adult. 61
161135 1979

Variations for Psoriasis 3

Expression for Psoriasis 3

Search GEO for disease gene expression data for Psoriasis 3.

Pathways for Psoriasis 3

GO Terms for Psoriasis 3

Biological processes related to Psoriasis 3 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 epidermis development GO:0008544 8.62 LCE1C CDSN

Sources for Psoriasis 3

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....